Supplementary Methods from Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

Lal, Shruti; Bhola, Neil E.; Sun, Bee-Chun; Chen, Yuping; Huang, Tom; Morton, Vivian; Chen, Kevin X.; Xia, Shanghua; Zhang, Haoyu; Parikh, Nehal S.; Ye, Qiuping; Veiby, O. Petter; Bellovin, David I.; Ji, Yuhua

doi:10.1158/2767-9764.24073405.v1

Supplementary Methods from Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

journal contribution

posted on 2023-09-01, 14:20 authored by Shruti Lal, Neil E. Bhola, Bee-Chun Sun, Yuping Chen, Tom Huang, Vivian Morton, Kevin X. Chen, Shanghua Xia, Haoyu Zhang, Nehal S. Parikh, Qiuping Ye, O. Petter Veiby, David I. Bellovin, Yuhua Ji

Supplementary Methods

Funding

ZaiLab (US) LLC

History

ARTICLE ABSTRACT

ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.

Usage metrics

Keywords

Dna Damage And Repair Small Molecule Agents Kinase inhibitors Drug Targets Protein kinase & phosphatase drug targets

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplementary Methods from Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

Funding

ZaiLab (US) LLC

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports